GlaxoSmithKline Pharmaceuticals Limited
GlaxoSmithKline Pharmaceuticals research, manufacture and make available a broad range of medicines and vaccines that benefit people.(Source : Company Web-site)
What GlaxoSmithKline files
- Others98
- Investor Meet25
- Updates20
- Important16
- Board Meeting12
- Dividend/Bonus9
GSK India posted a strong Q1 FY27, with revenue growing 15% to ₹924 Cr. Profit (PAT) jumped 24% to ₹253 Cr, achieving an EPS of ₹14.95. EBITDA also increased 17% to ₹293 Cr, driven by improved margins. This robust performance stems from a successful portfolio transformation strategy and execution excellence....
**Business Performance:** GSK India delivered strong FY26 financials with standalone revenue at ₹3,790 Cr (+2% YoY) and record Profit After Tax (PAT) of ₹1,010 Cr (+10% YoY). Q4 revenue was ₹989 Cr (+2% YoY) with PAT at ₹275 Cr (+6% YoY), despite some supply/vaccine challenges. GSK's represented market grew 7.3%,...
Here's a concise, retail-friendly summary: **Business Performance:** GSK Pharma reported solid Q3 results: Revenue at ₹1023 Cr (+8.1%), PAT at ₹277 Cr (+21.3%), and EBITDA at ₹368 Cr (+26.7%). General Medicines, Specialty, and Pediatric Vaccines were key drivers, leading to 10.5% in-market growth. **Growth Drivers or Strategy:** Strategic focus areas...
GSK Pharma's Q2 revenue hit ₹974 Cr, a 2.6% dip due to supply constraints & GST changes. Yet, profits (PAT) grew 3.3% to ₹253 Cr, and EBITDA climbed 4.9% to ₹335 Cr, driven by stronger margins. EPS stands at ₹15.06 (+3%). Growth engines include robust performance in Specialty segments like...
Here is the summary for GlaxoSmithKline Pharmaceuticals Limited: **Financial Highlights:** GSK Pharma's Q1 FY26 revenue was ₹805 Cr (-0.8% YoY), impacted by General Medicine seasonality. However, PAT surged 12.7% to ₹205 Cr (25.6% margin). EBITDA grew 9.3% to ₹251 Cr, with margins at 31.2% (+290 bps), driven by improved gross...